You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 97 No. 2, February 1979 TABLE OF CONTENTS
  Archives
  •  Online Features
  CLINICAL SCIENCES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (9)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Tumor-Associated Antibodies in the Serum of Patients With Ocular Melanoma

III. Immunoperoxidase Detection

Norman T. Felberg, PhD; J. Miguel Pro-Landazuri, MD; Jerry A. Shields, MD; Jay L. Federman, MD

Arch Ophthalmol. 1979;97(2):256-259.


Abstract

• The indirect immunofluorescent and indirect immunoperoxidase methods to detect tumor-associated antibodies (TAAs) in the plasma of patients with ocular melanomas were examined with commercially available conjugates. Testing indicated comparable titers and staining between the two techniques using snap-frozen uveal melanoma cells.

With the indirect immunoperoxidase method it was found that 78% (57) of 73 patients with uveal melanoma had TAAs, while 24% (25) of 106 control subjects were positive for TAAs (P < .001). Seventy-eight percent (11) of 14 patients with metastases to the choroid also had TAAs using snap-frozen cells from choroidal melanoma tumors, which indicates that it was not possible to distinguish this group of patients from those patients with primary uveal melanoma.

Tumor-associated antibodies have not been correlated to various prognostic indicators, but serial testing after therapy may show the biologic meaning of such antibodies in patients with ocular melanoma.



Author Affiliations

From the Retina Research Laboratory (Drs Federman and Pro-Landazuri), the Oncology Unit of the Retina Service (Dr Shields), and the Research Institute (Dr Felberg), Wills Eye Hospital, Philadelphia.


Footnotes

Accepted for publication May 1, 1978.

Reprint requests to Retina Research Laboratory, Wills Eye Hospital, 1601 Spring Garden St, Philadelphia, PA 19130 (Dr Federman).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Orbital Metastasis From Prostatic Carcinoma: Identification by an Immunoperoxidase Technique
Winkler et al.
Arch Ophthalmol 1981;99:1406-1408.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1979 American Medical Association. All Rights Reserved.